Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures

Phase 2

Not yet recruiting

Conditions: Metastatic Cancer Lung
Advanced Lung Cancer
CBNPC Cancer

Interventions: Drug: Atezolizumab 1200 mg IV
Drug: Tiragolumab 600 mg IV

First Posted Date: 2024-12-03

Last Posted Date: 2024-12-03

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 115

Registration Number: NCT06713798

Locations: 🇫🇷
Centre Hospitalier Cote Basque, Bayonne, France
🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Centre GF Leclerc, Dijon, France

and more 2 locations

Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for P53abn Endometrial Cancer

Phase 3

Recruiting

Conditions: Endometrial Cancer
P53abn

Interventions: Drug: Olaparib (300 mg BID)

First Posted Date: 2024-12-02

Last Posted Date: 2024-12-02

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 554

Registration Number: NCT06712472

Locations: 🇫🇷
Centre Hospitalier D'Albi, Albi, France
🇫🇷
Centre Hospitalier de Carcassonne, Carcassonne, France
🇫🇷
Chu Dijon, Dijon, France

and more 12 locations

A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

Phase 1

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Dato-DXd
Drug: Durvalumab

First Posted Date: 2024-07-18

Last Posted Date: 2024-07-22

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 50

Registration Number: NCT06508216

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

STEpwise Research Program to Promote INGeniouS ONline Supportive Solutions in the Relief of Cancer-related Fatigue (STEPPING-STONe)

Not Applicable

Not yet recruiting

Conditions: Moderate or Severe Score of Cancer-related Fatigue (CRF)
Cancer Diagnosis

Interventions: Device: Educational material plus self-management program - guided version with mental health professional
Device: Educational material plus self-management program - self-administered version
Device: Educational content

First Posted Date: 2024-07-17

Last Posted Date: 2024-12-11

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 372

Registration Number: NCT06505590

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

PROACT is a Prospective Master Protocol for a Cohort Study Focused on Evaluating the Implementation of Integrated Proactive Supportive Care Pathways at Gustave Roussy

Recruiting

Conditions: Any Cancer

Interventions: Other: Supportive Care Pathway

First Posted Date: 2024-06-27

Last Posted Date: 2024-07-29

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 210

Registration Number: NCT06479057

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer

Phase 1

Recruiting

Conditions: Oligometastatic Disease
Solid Tumor, Adult

Interventions: Drug: all-trans retinoic acid
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2024-06-03

Last Posted Date: 2024-07-12

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 58

Registration Number: NCT06439888

Locations: 🇫🇷
Gustave Roussy, Villejuif, France
🇫🇷
Centre Léon Bérard, Lyon, France

Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal Adenocarcinoma

Phase 3

Recruiting

Conditions: Adult With Intermediate Low or Mid Rectal Adenocarcinoma

Interventions: Radiation: contact X-ray brachytherapy (CXB)

First Posted Date: 2024-05-07

Last Posted Date: 2024-05-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 212

Registration Number: NCT06402864

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

CARE1 Pragmatic Clinical Trial

Phase 3

Recruiting

Conditions: Metastatic Kidney Cancer
Metastatic Kidney Carcinoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Pembrolizumab
Drug: Cabozantinib
Drug: Axitinib
Drug: Lenvatinib

First Posted Date: 2024-04-15

Last Posted Date: 2024-04-19

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 1250

Registration Number: NCT06364631

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

tislelizUMaB in canceR Patients With molEcuLar residuaL Disease

Phase 3

Not yet recruiting

Conditions: Cancer
Colo-rectal Cancer
Soft Tissue Sarcoma
Lung Cancer
Pancreas Cancer

Interventions: Other: Blood sampling
Drug: Tislelizumab
Drug: Placebo

First Posted Date: 2024-03-27

Last Posted Date: 2024-05-16

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 717

Registration Number: NCT06332274

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

Phase 1

Recruiting

Conditions: Breast Cancer Metastatic
HER2 Low Breast Carcinoma
HER2-positive Metastatic Breast Cancer
Advanced Breast Cancer

Interventions: Drug: Patritumab deruxtecan
Drug: Olaparib

First Posted Date: 2024-03-07

Last Posted Date: 2024-03-29

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 152

Registration Number: NCT06298084

Locations: 🇫🇷
Gustave Roussy Institut, Villejuif, France

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy